Ironwood Pharmaceuticals Valuation
| IRWD Stock | USD 3.44 0.10 2.99% |
At this time, the firm appears to be undervalued. Ironwood Pharmaceuticals retains a regular Real Value of $6.63 per share. The prevalent price of the firm is $3.44. Our model calculates the value of Ironwood Pharmaceuticals from evaluating the firm fundamentals such as Return On Asset of 0.13, return on equity of -5.75, and Current Valuation of 1.08 B as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Ironwood Pharmaceuticals' valuation include:
Price Book 2.5899 | Enterprise Value 1.1 B | Enterprise Value Ebitda 10.1457 | Price Sales 1.4547 | Forward PE 12.3305 |
Undervalued
Today
Please note that Ironwood Pharmaceuticals' price fluctuation is slightly risky at this time. Calculation of the real value of Ironwood Pharmaceuticals is based on 3 months time horizon. Increasing Ironwood Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Ironwood stock is determined by what a typical buyer is willing to pay for full or partial control of Ironwood Pharmaceuticals. Since Ironwood Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Ironwood Stock. However, Ironwood Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.44 | Real 6.63 | Target 16.5 | Hype 3.61 | Naive 2.74 |
The real value of Ironwood Stock, also known as its intrinsic value, is the underlying worth of Ironwood Pharmaceuticals Company, which is reflected in its stock price. It is based on Ironwood Pharmaceuticals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Ironwood Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Ironwood Pharmaceuticals helps investors to forecast how Ironwood stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Ironwood Pharmaceuticals more accurately as focusing exclusively on Ironwood Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Ironwood Pharmaceuticals' intrinsic value based on its ongoing forecasts of Ironwood Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Ironwood Pharmaceuticals' closest peers. If more than one evaluation category is relevant for Ironwood Pharmaceuticals we suggest using both methods to arrive at a better estimate.
Ironwood Pharmaceuticals Cash |
|
Ironwood Valuation Trend
Comparing Ironwood Pharmaceuticals' enterprise value against its market capitalization is a good way to estimate the value of Ironwood Pharmaceuticals uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Ironwood Revenue by Product
Ironwood Pharmaceuticals Total Value Analysis
Ironwood Pharmaceuticals is currently anticipated to have valuation of 1.08 B with market capitalization of 550.5 M, debt of 715.54 M, and cash on hands of 504.36 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Ironwood Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.08 B | 550.5 M | 715.54 M | 504.36 M |
Ironwood Pharmaceuticals Investor Information
About 98.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.01. Ironwood Pharmaceuticals last dividend was issued on the 2nd of April 1970. The entity had 1194:1000 split on the 2nd of April 2019. Based on the key indicators related to Ironwood Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Ironwood Pharmaceuticals may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Ironwood Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Ironwood Pharmaceuticals has an asset utilization ratio of 93.98 percent. This indicates that the Company is making $0.94 for each dollar of assets. An increasing asset utilization means that Ironwood Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Ironwood Pharmaceuticals Ownership Allocation
The majority of Ironwood Pharmaceuticals outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Ironwood Pharmaceuticals to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Ironwood Pharmaceuticals. Please pay attention to any change in the institutional holdings of Ironwood Pharmaceuticals as this could imply that something significant has changed or is about to change at the company.Ironwood Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 442.74 M. Net Loss for the year was (1 B) with profit before overhead, payroll, taxes, and interest of 366.33 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Ironwood Pharmaceuticals' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Ironwood Pharmaceuticals and how it compares across the competition.
About Ironwood Pharmaceuticals Valuation
The stock valuation mechanism determines Ironwood Pharmaceuticals' current worth on a weekly basis. Our valuation model uses a comparative analysis of Ironwood Pharmaceuticals. We calculate exposure to Ironwood Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Ironwood Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 441.2 M | 224 M | |
| Pretax Profit Margin | (2.14) | (2.25) | |
| Operating Profit Margin | 0.47 | 0.50 | |
| Net Loss | (2.26) | (2.38) | |
| Gross Profit Margin | 1.00 | 0.74 |
Ironwood Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as Ironwood Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 155.4 M | |
| Quarterly Earnings Growth Y O Y | -0.773 | |
| Forward Price Earnings | 12.3305 |
Ironwood Pharmaceuticals Current Valuation Indicators
Valuation refers to the process of determining the present value of Ironwood Pharmaceuticals and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Ironwood we look at many different elements of the entity such as Ironwood's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Ironwood Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Ironwood Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Ironwood Pharmaceuticals' worth.Complementary Tools for Ironwood Stock analysis
When running Ironwood Pharmaceuticals' price analysis, check to measure Ironwood Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ironwood Pharmaceuticals is operating at the current time. Most of Ironwood Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ironwood Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ironwood Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ironwood Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |